At a glance
- Originator Point Therapeutics; Tufts University
- Class Antihyperglycaemics; Pyrrolidines; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Type 2 diabetes mellitus